Inhibitors of MDM2 and MDMX: A structural perspective

Future Medicinal Chemistry

Volumn 1, Issue 6, 2009, Pages 1075-1094

  Riedinger, Christiane ^a   McDonnell, James M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINEDIONE; CHALCONE; CHLOROFUSIN; DIAZEPINE DERIVATIVE; HEXYLITACONIC ACID; MI 17; MI 219; MI 43; MI 63; NU 8231; NUTLIN 1; NUTLIN 2; NUTLIN 3; NXN 6; NXN 7; PEPTIDE 8; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; SPIROOXINDOLE; SULFONAMIDE; SYC; UNCLASSIFIED DRUG;

BINDING AFFINITY; DOWN REGULATION; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; INDOLES; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASMS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77953424554     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.75     Document Type: Review

References (149)

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997).
2. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19, 607-614 (2002).
3. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77, 81-137 (2000).
4. Blagosklonny MV. p53: a ubiquitous target of anticancer drugs. Int. J. Cancer 98, 161-166 (2002).
5. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 26, 3453-3459 (1998).
6. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6, 909-923 (2006).
7. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323-1334 (2006).
8. Xue W, Zender L, Miething C et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660 (2007).
9. Ventura A, Kirsch DG, McLaughlin ME et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661-665 (2007).
10. Kussie PH, Gorina S, Marechal V et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953 (1996).
11. Popowicz GM, Czarna A, Rothweiler U et al. Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle 6, 2386-2392 (2007).
12. Lane DP. Cancer. p53, guardian of the genome. Nature 358, 15-16 (1992).
13. Stenger JE, Mayr GA, Mann K, Tegtmeyer P. Formation of stable p53 homotetramers and multiples of tetramers. Mol. Carcinog. 5, 102-106 (1992).
14. Fields S, Jang SK. Presence of a potent transcription activating sequence in the p53 protein. Science 249, 1046-1049 (1990).
15. Raycroft L, Wu HY, Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249, 1049-1051 (1990).
16. Chang J, Kim DH, Lee SW, Choi KY, Sung YC. Transactivation ability of p53 transcriptional activation domain is directly related to the binding affinity to TATAbinding protein. J. Biol. Chem. 270, 25014-25019 (1995).
17. Walker KK, Levine AJ. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl Acad. Sci. USA 93, 15335-15340 (1996).
18. Dawson R, Muller L, Dehner A, Klein C, Kessler H, Buchner J. The N-terminal domain of p53 is natively unfolded. J. Mol. Biol. 332, 1131-1141 (2003).
19. Bennett MJ, Choe S, Eisenberg D. Domain swapping: entangling alliances between proteins. Proc. Natl Acad. Sci. USA 91, 3127-3131 (1994).
20. Vousden KH, Lane DP. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8, 275-283 (2007).
21. Berman HM, Westbrook J, Feng Z et al. The protein data bank. Nucleic Acids Res. 28, 235-242 (2000).
22. Canadillas JM, Tidow H, Freund SM, Rutherford TJ, Ang HC, Fersht AR. Solution structure of p53 core domain: structural basis for its instability. Proc. Natl Acad. Sci. USA 103, 2109-2114 (2006).
23. Jeffrey PD, Gorina S, Pavletich NP. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267, 1498-1502 (1995).
24. Veprintsev DB, Freund SM, Andreeva A et al. Core domain interactions in full-length p53 in solution. Proc. Natl Acad. Sci. USA 103, 2115-2119 (2006).
25. Lee S, Elenbaas B, Levine A, Griffith J. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/ deletion mismatches. Cell 81, 1013-1020 (1995).
26. Tidow H, Melero R, Mylonas E et al. Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex. Proc. Natl Acad. Sci. USA 104, 12324-12329 (2007).
27. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Annu. Rev. Biochem. 77, 557-582 (2008).
28. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 408, 307-310 (2000).
29. Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ. 13, 941-950 (2006).
30. Vousden KH. Outcomes of p53 activation-spoilt for choice. J. Cell Sci. 119, 5015-5020 (2006).
31. Lukas J, Lukas C, Bartek J. Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. DNA Repair (Amst.) 3, 997-1007 (2004).
32. Munger K. Disruption of oncogene/tumor suppressor networks during human carcinogenesis. Cancer Invest. 20, 71-81 (2002).
33. Vousden KH. Apoptosis. p53 and PUMA: a deadly duo. Science 309, 1685-1686 (2005).
34. Cahilly-Snyder L, Yang-Feng T, Francke U, George DL. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat. Cell Mol. Genet. 13, 235-244 (1987).
35. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic portential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10, 1565-1569 (1991).
36. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358, 80-83 (1992).
37. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245 (1992).
38. Brown DR, Deb S, Munoz RM, Subler MA, Deb SP. The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein. Mol. Cell Biol. 13, 6849-6857 (1993).
39. Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17, 554-564 (1998).
40. Argentini M, Barboule N, Wasylyk B. The contribution of the acidic domain of MDM2 to p53 and MDM2 stability. Oncogene 20, 1267-1275 (2001).
41. Wang Q, Yang Y, Wang L, Zhang PZ, Yu L. Acidic domain is indispensable for MDM2 to negatively regulate the acetylation of p53. Biochem. Biophys. Res. Commun. 374, 437-441 (2008).
42. Wawrzynow B, Pettersson S, Zylicz A et al. A function for the RING finger domain in the allosteric control of MDM2 conformation and activity. J. Biol. Chem. 284, 11517-11530 (2009).
43. Brown DR, Thomas CA, Deb SP. The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycleinhibitory function induces tumorigenesis. Embo. J. 17, 2513-2525 (1998).
44. Yu GW, Allen MD, Andreeva A, Fersht AR, Bycroft M. Solution structure of the C4 zinc finger domain of HDM2. Protein Sci. 15, 384-389 (2006).
45. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420, 25-27 (1997).
46. Boyd SD, Tsai KY, Jacks T. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat. Cell Biol. 2, 563-568 (2000).
47. Kostic M, Matt T, Martinez-Yamout MA, Dyson HJ, Wright PE. Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53. J. Mol. Biol. 363, 433-450 (2006).
48. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378, 206-208 (1995).
49. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203-206 (1995).
50. Donehower LA, Harvey M, Slagle BL et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221 (1992).
51. McMasters KM, Montes de Oca Luna R, Pena JR, Lozano G. mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts. Oncogene 13, 1731-1736 (1996).
52. Silva J, Silva JM, Dominguez G et al. Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. J. Pathol. 199, 289-297 (2003).
53. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92, 725-734 (1998).
54. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83, 993-1000 (1995).
55. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell Biol. 1, 20-26 (1999).
56. Picksley SM, Lane DP. The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays 15, 689-690 (1993).
57. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7, 1126-1132 (1993).
58. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. Embo. J. 12, 461-468 (1993).
59. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell Biol. 13, 4107-4114 (1993).
60. Tao W, Levine AJ. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. 96, 3077-3080 (1999).
61. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299 (1997).
62. Marine JC, Dyer MA, Jochemsen AG. MDMX: from bench to bedside. J. Cell Sci. 120, 371-378 (2007).
63. Wade M, Wahl GM. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol. Cancer Res. 7, 1-11 (2009).
64. Shvarts A, Bazuine M, Dekker P et al. Isolation and identification of the human homolog of a new p53-binding protein, Mdmx. Genomics 43, 34-42 (1997).
65. Bottger V, Bottger A, Garcia-Echeverria C et al. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 18, 189-199 (1999).
66. Marine JC, Jochemsen AG. Mdmx as an essential regulator of p53 activity. Biochem. Biophys. Res. Commun. 331, 750-760 (2005).
67. Stad R, Ramos YF, Little N et al. Hdmx stabilizes mdm2 and p53. J. Biol. Chem. 275, 28039-28044 (2000).
68. Migliorini D, Danovi D, Colombo E, Carbone R, Pelicci PG, Marine JC. Hdmx recruitment into the nucleus by Hdm2 is essential for its ability to regulate p53 stability and transactivation. J. Biol. Chem. 277, 7318-7323 (2002).
69. Sharp DA, Kratowicz SA, Sank MJ, George DL. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J. Biol. Chem. 274, 38189-38196 (1999).
70. Tanimura S, Ohtsuka S, Mitsui K, Shirouzu K, Yoshimura A, Ohtsubo M. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett. 447, 5-9 (1999).
71. Linares LK, Hengstermann A, Ciechanover A, Muller S, Scheffner M. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc. Natl Acad. Sci. USA 100, 12009-12014 (2003).
72. Gu J, Nie L, Kawai H, Yuan ZM. Subcellular distribution of p53 and p73 are differentially regulated by MDM2. Cancer Res. 61, 6703-6707 (2001).
73. Jackson MW, Berberich SJ. MdmX protects p53 from Mdm2-mediated degradation. Mol. Cell Biol. 20, 1001-1007 (2000).
74. Mayo LD, Turchi JJ, Berberich SJ. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res. 57, 5013-5016 (1997).
75. Zuckerman V, Lenos K, Popowicz GM et al. c-Abl phosphorylates Hdmx and regulates its interaction with p53. J. Biol. Chem. 284, 4031-4039 (2009).
76. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362, 857-860 (1993).
77. Wallace M, Worrall E, Pettersson S, Hupp TR, Ball KL. Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol. Cell 23, 251-263 (2006).
78. Shimizu H, Burch LR, Smith AJ et al. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J. Biol. Chem. 277, 28446-28458 (2002).
79. Yu GW, Rudiger S, Veprintsev D, Freund S, Fernandez-Fernandez MR, Fersht AR. The central region of HDM2 provides a second binding site for p53. Proc. Natl Acad. Sci. USA 103, 1227-1232 (2006).
80. Uhrinova S, Uhrin D, Powers H et al. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J. Mol. Biol. 350, 587-598 (2005).
81. McCoy MA, Gesell JJ, Senior MM, Wyss DF. Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation. Proc. Natl Acad. Sci. USA 100, 1645-1648 (2003).
82. Sakurai K, Chung HS, Kahne D. Use of a retroinverso p53 peptide as an inhibitor of MDM2. J. Am. Chem. Soc. 126, 16288-16289 (2004).
83. Popowicz GM, Czarna A, Holak TA. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle 7, 2441-2443 (2008).
84. Garcia-Echeverria C, Chene P, Blommers MJ, Furet P. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. J. Med. Chem. 43, 3205-3208 (2000).
85. Kallen J, Goepfert A, Blechschmidt A et al. Crystal structures of human MdmX (HdmX) in complex with p53 Peptide analogues reveal surprising conformational changes. J. Biol. Chem. 284, 8812-8821 (2009).
86. Cochran AG. Protein-protein interfaces: mimics and inhibitors. Curr. Opin. Chem. Biol. 5, 654-659 (2001).
87. Stites WE. Protein-protein interactions: interface structure, binding thermodynamics, and mutational analysis. Chem. Rev. 97, 1233-1250 (1997).
88. He MM, Smith AS, Oslob JD et al. Small-molecule inhibition of TNF-α. Science 310, 1022-1025 (2005).
89. Arkin MR, Randal M, DeLano WL et al. Binding of small molecules to an adaptive protein-protein interface. Proc. Natl Acad. Sci. USA 100, 1603-1608 (2003).
90. Braisted AC, Oslob JD, Delano WL et al. Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. J. Am. Chem. Soc. 125, 3714-3715 (2003).
91. Tian SS, Lamb P, King AG et al. A small nonpeptidyl mimic of granulocyte-colonystimulating factor. Science 281, 257-259 (1998).
92. Petros AM, Dinges J, Augeri DJ et al. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J. Med. Chem. 49, 656-663 (2006).
93. Oltersdorf T, Elmore SW, Shoemaker AR et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681 (2005).
94. Yoakim C, Ogilvie WW, Goudreau N et al. Discovery of the first series of inhibitors of human papillomavirus type 11: inhibition of the assembly of the E1-E2-Origin DNA complex. Bioorg. Med. Chem. Lett. 13, 2539-2541 (2003).
95. Goudreau N, Cameron DR, Deziel R et al. Optimization and determination of the absolute configuration of a series of potent inhibitors of human papillomavirus type-11 E1-E2 protein-protein interaction: a combined medicinal chemistry, NMR and computational chemistry approach. Bioorg. Med. Chem. 15, 2690-2700 (2007).
96. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450, 1001-1009 (2007).
97. Sakurai K, Schubert C, Kahne D. Crystallographic analysis of an 8-mer p53 peptide analogue complexed with MDM2. J. Am. Chem. Soc. 128, 11000-11001 (2006).
98. DeLano WL, Ultsch MH, de Vos AM, Wells JA. Convergent solutions to binding at a protein-protein interface. Science 287, 1279-1283 (2000).
99. Klein C, Vassilev LT. Targeting the p53-MDM2 interaction to treat cancer. Br. J. Cancer 91, 1415-1419 (2004).
100. Bottger V, Bottger A, Howard SF et al. Identification of novel mdm2 binding peptides by phage display. Oncogene 13, 2141-2147 (1996).
101. Picksley SM, Vojtesek B, Sparks A, Lane DP. Immunochemical analysis of the interaction of p53 with MDM2-fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 9, 2523-2529 (1994).
102. Bottger A, Bottger V, Garcia-Echeverria C et al. Molecular characterization of the hdm2-p53 interaction. J. Mol. Biol. 269, 744-756 (1997).
103. Stoll R, Renner C, Hansen S et al. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 40, 336-344 (2001).
104. Zhao J, Wang M, Chen J et al. The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. Cancer Lett. 183, 69-77 (2002).
105. Duncan SJ, Gruschow S, Williams DH et al. Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J. Am. Chem. Soc. 123, 554-560 (2001).
106. Dore JC, Viel C. Antitumor chemotherapy. IX. Cytotoxic activity in cultured tumor cells of chalcone substituants and related compounds. J. Pharm. Belg. 29, 341-351 (1974).
107. Tsukamoto S, Yoshida T, Hosono H, Ohta T, Yokosawa H. Hexylitaconic acid: a new inhibitor of p53-HDM2 interaction isolated from a marine-derived fungus, Arthrinium sp. Bioorg. Med. Chem. Lett. 16, 69-71 (2006).
108. Galatin PS, Abraham DJ. A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells. J. Med. Chem. 47, 4163-4165 (2004).
109. Hardcastle IR, Ahmed SU, Atkins H et al. Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction. Bioorg. Med. Chem. Lett. 15, 1515-1520 (2005).
110. Hardcastle IR, Ahmed SU, Atkins H et al. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. J. Med. Chem. 49, 6209-6221 (2006).
111. Riedinger C, Endicott JA, Kemp SJ et al. Analysis of chemical shift changes reveals the binding modes of isoindolinone inhibitors of the MDM2-p53 interaction. J. Am. Chem. Soc. 130, 16038-16044 (2008).
112. Rothweiler U, Czarna A, Krajewski M et al. Isoquinolin-1-one inhibitors of the MDM2-p53 interaction. ChemMedChem 3, 1118-1128 (2008).
113. Domling A. Small molecular weight protein-protein interaction antagonists: an insurmountable challenge? Curr. Opin. Chem. Biol. 12, 281-291 (2008).
114. Vassilev LT, Vu BT, Graves B et al. In vivo activation of the p53 pathway by smallmolecule antagonists of MDM2. Science 303, 844-848 (2004).
115. Fry DC, Emerson SD, Palme S, Vu BT, Liu CM, Podlaski F. NMR structure of a complex between MDM2 and a small molecule inhibitor. J. Biomol. NMR 30, 163-173 (2004).
116. Tovar C, Rosinski J, Filipovic Z et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl Acad. Sci. USA 103, 1888-1893 (2006).
117. Pantoliano MW, Petrella EC, Kwasnoski JD et al. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J. Biomol. Screen 6, 429-440 (2001).
118. Parks DJ, Lafrance LV, Calvo RR et al. 1,4-benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR. Bioorg. Med. Chem. Lett. 15, 765-770 (2005).
119. Grasberger BL, Lu T, Schubert C et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J. Med. Chem. 48, 909-912 (2005).
120. Majeux N, Scarsi M, Caflisch A. Efficient electrostatic solvation model for proteinfragment docking. Proteins 42, 256-268 (2001).
121. Cummings MD, Schubert C, Parks DJ et al. Substituted 1,4-benzodiazepine- 2,5-diones as α-helix mimetic antagonists of the HDM2-p53 protein-protein interaction. Chem. Biol. Drug Des. 67, 201-205 (2006).
122. Koblish HK, Zhao S, Franks CF et al. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol. Cancer Ther. 5, 160-169 (2006).
123. Parks DJ, LaFrance LV, Calvo RR et al. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design. Bioorg. Med. Chem. Lett. 16, 3310-3314 (2006).
124. Ding K, Lu Y, Nikolovska-Coleska Z et al. Structure-based design of potent non-peptide MDM2 inhibitors. J. Am. Chem. Soc. 127, 10130-10131 (2005).
125. Ding K, Lu Y, Nikolovska-Coleska Z et al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J. Med. Chem. 49, 3432-3435 (2006).
126. Shangary S, Qin D, McEachern D et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl Acad. Sci. USA 105, 3933-3938 (2008).
127. Shangary S, Ding K, Qiu S et al. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol. Cancer Ther. 7, 1533-1542 (2008).
128. Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J. Biol. Chem. 281, 33030-33035 (2006).
129. Wade M, Wong ET, Tang M, Stommel JM, Wahl GM. Hdmx modulates the outcome of p53 activation in human tumor cells. J. Biol. Chem. 281, 33036-33044 (2006).
130. Laurie NA, Donovan SL, Shih CS et al. Inactivation of the p53 pathway in retinoblastoma. Nature 444, 61-66 (2006).
131. Hu B, Gilkes DM, Chen J. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res. 67, 8810-8817 (2007).
132. Czarna A, Popowicz GM, Pecak A, Wolf S, Dubin G, Holak TA. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx. Cell Cycle 8, 1176-1184 (2009).
133. Pazgier M, Liu M, Zou G et al. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc. Natl Acad. Sci. USA DOI: 10.1073/ pnas.0900947106 (2009) (Epub ahead of print).
134. Hara T, Durell SR, Myers MC, Appella DH. Probing the structural requirements of peptoids that inhibit HDM2-p53 interactions. J. Am. Chem. Soc. 128, 1995-2004 (2006).
135. Chen L, Yin H, Farooqi B, Sebti S, Hamilton AD, Chen J. p53 α-helix mimetics antagonize p53/MDM2 interaction and activate p53. Mol. Cancer Ther. 4, 1019-1025 (2005).
136. Kalid O, Ben-Tal N. Study of MDM2 binding to p53-analogues: affinity, helicity, and applicability to drug design. J. Chem. Inf. Model 49, 865-876 (2009).
137. Kritzer JA, Stephens OM, Guarracino DA, Reznik SK, Schepartz A. β-peptides as inhibitors of protein-protein interactions. Bioorg. Med. Chem. 13, 11-16 (2005).
138. Harker EA, Daniels DS, Guarracino DA, Schepartz A. β-peptides with improved affinity for hDM2 and hDMX. Bioorg. Med. Chem. 17, 2038-2046 (2009).
139. Kritzer JA, Hodsdon ME, Schepartz A. Solution structure of a β-peptide ligand for hDM2. J. Am. Chem. Soc. 127, 4118-4119 (2005).
140. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 278, 261-263 (1979).
141. Linzer DI, Levine AJ. Characterization of a 54 kDa cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17, 43-52 (1979).
142. DeLeo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl Acad. Sci. USA 76, 2420-2424 (1979).
143. Eliyahu D, Raz A, Gruss P, Givol D, Oren M. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 312, 646-649 (1984).
144. Parada LF, Land H, Weinberg RA, Wolf D, Rotter V. Cooperation between gene encoding p53 tumour antigen and Ras in cellular transformation. Nature 312, 649-651 (1984).
145. Jenkins JR, Rudge K, Currie GA. Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature 312, 651-654 (1984).
146. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 30, 1083-1093 (1989).
147. Kern SE, Kinzler KW, Bruskin A et al. Identification of p53 as a sequence-specific DNA-binding protein. Science 252, 1708-1711 (1991).
148. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl Acad. Sci. USA 89, 7491-7495 (1992).
149. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2, 594-604 (2002).